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ABSTRACT  
 
Hyaluronan (HA) is a glycosaminoglycan synthesized directly into the extracellular matrix by 
three hyaluronan synthases (HAS1, HAS2, and HAS3). HA is abundantly synthesized by 
keratinocytes but its epidermal functions remain unclear. We used culture models to grow 
human keratinocytes as autocrine monolayers or as reconstructed human epidermis (RHE) to 
assess HA synthesis and HAS expression levels during the course of keratinocyte 
differentiation. In both models, epidermal differentiation downregulates HAS3 mRNA 
expression while increasing HAS1 without significant changes in hyaluronidase expression. 
HA production correlates with HAS1 mRNA expression level during normal differentiation. 
To investigate the regulation of HAS gene expression during inflammatory conditions linked 
to perturbed differentiation, lesional and non-lesional skin biopsies of atopic dermatitis (AD) 
patients were analyzed. HAS3 mRNA expression level increases in AD lesions compared to 
healthy and non-lesional skin. Simultaneously, HAS1 expression decreases. Heparin-binding 
EGF-like growth factor (HB-EGF) is upregulated in AD epidermis. An AD-like HAS 
expression pattern is observed in RHE incubated with HB-EGF. These results indicate that 
HAS1 is the main enzyme responsible for HA production by normal keratinocytes and thus, 
must be considered as an actor of normal keratinocyte differentiation. In contrast, HAS3 can be 
induced by HB-EGF and seems mainly involved in AD epidermis. 
  
INTRODUCTION 
 
Hyaluronan (HA) is an essential extracellular polysaccharide. Its abundance in dermis and 
epidermis contrasts with the lack of understanding of its functions in skin. HA is composed of 
alternating glucuronic acid and N-acetylglucosamine residues repeated several thousands of 
times to form a linear non-sulfated glycosaminoglycan (Toole, 2004). HA is produced at the 
inner cell membrane and directly exported to the extracellular space by three enzymes called 
hyaluronan synthases (HAS) 1, 2 and 3 (Rilla et al., 2005). The three HASs differ by their 
temporal expression during development, their specific activity, and the size of the respective 
HA polymers they produce (Itano et al., 1999). HAS2 appears to play a key role during 
development since deletion of its gene in mice is lethal at mid-gestation, due to multiple 
cardiovascular malformations (Camenisch et al., 2000). On the other hand, HAS1 and HAS3 
null mice are viable (Bai et al., 2005; Kobayashi et al., 2010) as well as double-knockout mice 
lacking HAS1 and HAS3 (Mack et al., 2011). Enzymatic catabolism of HA is performed by 
hyaluronidases, mainly HYAL1 and HYAL2 (Toole, 2004). The skin contains 50% of the total 
body HA (Meyer and Stern, 1994). Labelling using a biotinylated HA-binding protein shows 
that HA is abundant in the dermis and to a lesser extent in the epidermis. In the latter, HA is 
mainly localised around the cells of basal and spinous layers (Tuhkanen et al., 1998). 
Involvement of HA and HASs in proliferation, differentiation, and migration of keratinocytes, 
as well as in the establishment of the epidermal barrier, has been reported (Maytin et al., 2004; 
Passi et al., 2004; Rilla et al., 2004; Bourguignon et al., 2006; Farwick et al., 2011). Yet the 
mechanisms of HA involvement in normal epidermis are not well identified or understood. 
Increased HA synthesis has been implicated in skin inflammation. An increase in HA staining 
parallel to an increase in HAS3 mRNA expression are observed in acute eczema (Ohtani et al., 
2009). HAS2 and HAS3 in keratinocytes can be upregulated by pro-inflammatory cytokines 
such as IL4, IL13, and IFN-γ (Sayo et al., 2002), by growth factors such as EGF or KGF 
(Karvinen et al., 2003; Pasonen-Seppanen et al., 2003), or by retinoic acid (Saavalainen et al., 
2005; Pasonen-Seppanen et al., 2008). However, the specific regulation of HAS genes during 
spontaneous proliferation and differentiation of keratinocytes or during the establishment of the 
epidermal barrier has not yet been characterized. 
Here, we have investigated HA synthesis in normal human keratinocytes using two culture 
models of epidermal differentiation induced by cell density, i.e. confluent keratinocyte 
monolayers and reconstructed human epidermis (RHE), both cultured without addition of 
molecules influencing the differentiation processes (Minner et al., 2010; Frankart et al., 2012), 
as well as in lesional and non-lesional skin from atopic dermatitis (AD) patients. Our data 
strikingly suggest that the balance of HA produced by distinct HASs is differentially involved 
in the regulation of keratinocyte physiology and pathophysiology: HAS1 is responsible for the 
bulk of HA production in normal keratinocytes, whereas HAS3 is prominent in pathological 
conditions. These observations pave the way to targeted HA modulation therapies. 
 
RESULTS 
 
Production of HA by human keratinocytes correlates with expression levels of HAS1 
during differentiation and dedifferentiation 
 
Autocrine cultures of human keratinocytes undergo differentiation as cells become confluent 
(Minner et al., 2010). HA concentration was measured in the culture medium, the pericellular 
zone, and the intracellular compartment of human keratinocyte monolayers before and after 
confluence. HA accumulates in the medium and around the cells mainly after culture confluence 
(figure 1a and 1b). The amount of intracellular HA (figure 1c) is variable while extracellular 
HA increases progressively and markedly with differentiation (figure 1a-b and figure 1e). One 
may surmise that pericellular HA continuously diffuses into the culture medium. This pattern 
of HA production suggests an active role concomitant with differentiation of keratinocytes. 
Because HA’s functions are size-dependent, we analyzed the molecular weight of newly 
synthesized HA released into the medium at different culture steps (supplementary figure 1a). 
Various sizes of HA were detected in each condition with a peak around ~2,000 kDa. There 
were no significant changes in HA molecular size during differentiation. 
To determine if one particular HAS is specifically involved in the enhanced production of HA 
by differentiating keratinocytes, the mRNA expression levels of HAS1, HAS2 and HAS3 were 
determined by quantitative PCR. The relative expression level of HAS1 mRNA increases 5-
fold at confluence and between 5 and 10-fold after confluence (figure 1d). In contrast, the 
relative expression levels of HAS2 and HAS3 mRNA decrease significantly as soon as cultures 
become confluent and express differentiation markers (figure 1e). We also measured the mRNA 
expression of HYAL1 and HYAL2 during the same timeframe (supplementary figure 2a and 
2b). Both are stable, suggesting that upregulation of HAS1 is the main driver of HA 
accumulation during differentiation. 
To probe the potential link between keratinocyte differentiation and expressions of specific 
HASs, confluent cultures were incubated for 18 h with various concentrations of all-trans 
retinoic acid (RA), a well-known inducer of epidermal dedifferentiation (Poumay et al., 1999; 
Giltaire et al., 2009). This treatment strongly downregulates keratin 10 (KRT10) and 
upregulates involucrin (IVL) (figure 1g). Simultaneously, the mRNA levels of HAS2 and HAS3 
dose-dependently increase while those of HAS1 decrease >10-fold. The effect of RA on HAS2 
and HAS3 expressions has been previously described (Kaya et al., 2005; Saavalainen et al., 
2005); our experiments highlight downregulation of HAS1 expression concomitantly with 
KRT10 disappearance (figure 1f).  
The role of the EGF receptor (EGFR) in the correlation between HAS expression and 
keratinocyte differentiation was then evaluated. EGFR, especially when phosphorylated 
(pEGFR), is known to regulate the expression of numerous genes involved in differentiation 
(Tran et al., 2012). The abundance of EGFR and pEGFR was assessed on Western blots before 
and after confluence of keratinocyte cultures. Both forms of EGFR are detected at progressively 
lower levels as keratinocytes differentiate and express higher amounts of KRT10 
(supplementary figure 3a). To test whether EGFR also controls the balance of HAS expression, 
subconfluent (C-2d) keratinocytes were treated with the EGFR-neutralizing antibody LA1 for 
48 h. LA1 blocks EGFR phosphorylation (supplementary figure 3b) while increasing HAS1 
expression 10-fold and decreasing HAS3 expression 10-fold (supplementary figure 3c). 
In summary, the HAS1/HAS3 expression ratio robustly correlates with keratinocyte 
differentiation state during both spontaneous differentiation and pharmacological treatments; 
EGFR may be involved in that switch.  
 
Depletion of HA synthesis does not modify the expression profile of keratinocyte 
differentiation markers 
 
Based on the preceding observations, HA may play a role in keratinocyte differentiation. To 
test this, keratinocyte monolayers were treated with either 4-methylumbelliferone (4MU), a 
widespread inhibitor of HA synthesis, or Streptomyces hyaluronidase, which degrades HA into 
small fragments. 4MU was previously shown to decrease rat keratinocyte proliferation at 
concentrations of 0.2–1.0 mM (Rilla et al., 2004). Using concentration-response experiments, 
we show that 0.5 mM 4MU is both effective (>75% decrease in HA release) and relatively non-
toxic (<25% cell mortality if treatment is started at C-2d) in cultured human keratinocytes 
(supplementary figure 4a and 4b). Hyaluronidase treatment removes all HA (supplementary 
figure 4c). However, exposure of cultures to either 0.5 mM 4MU or 1 U/ml Streptomyces 
hyaluronidase during 48 h did not modify the expression profile of KRT10, IVL or FLG over 
the course of keratinocyte differentiation (figure 2). 
We conclude that HA synthesis is not involved in the differentiation process of human 
keratinocytes. 
 
Production of HA during the reconstruction of human epidermis also correlates with 
HAS1 expression 
 
The RHE with its air-liquid interface is a more physiological model of the epidermis that can 
be studied without influence of the dermis (Frankart et al., 2012). The amount of HA released 
in the RHE medium increases progressively during reconstruction (figure 3a). The HA amount 
in the tissue is about 100-fold the amount measured in the medium and increases in a similar 
way during reconstruction (figure 3b). After 11 days, there is twice as much HA as there are 
proteins (2 µg HA per µg of total cell protein). Fluorescent detection of HA in RHE sections 
shows a faint labelling after 1, 3, and 5 days and a dramatic increase after 7, 9, and 11 days of 
growth as the tissue stratifies and accumulates KRT10 and IVL suprabasally (figure 3c). HA 
labelling surrounds all keratinocytes throughout the epithelium. This pattern mimics the 
location of HA in normal epidermis in vivo (see figure 5). 
The mRNA expression levels of HASs and hyaluronidases were also measured in RHE using 
quantitative PCR. HAS2 is scarcely expressed in RHE, becoming detectable after 40 cycles of 
PCR only (data not shown). The level of HAS1 mRNA expression is stable over the duration 
of the culture (figure 4). In contrast, HAS3 expression progressively decreases from the third 
day on, as soon as RHE expresses differentiation markers. A similar expression pattern is 
observed for HYAL1 and HYAL2 (supplementary figure 2c and 2d).  
The size of HA released by RHE at various time points was analyzed using chromatography, 
revealing a broad profile of molecular sizes (supplementary figure 1b) similar to that of the 
monolayers (supplementary figure 1a). This profile does not change significantly during RHE 
differentiation. 
 
Detectable HA is strongly increased in lesional epidermis of atopic dermatitis patients and 
correlates with downregulation of HAS1 and upregulation of HAS3 
 
Previous studies have shown a link between HA and inflammatory skin diseases (Jameson et 
al., 2005; Ohtani et al., 2009; Barnes et al., 2012). HA distribution and HAS expression levels 
were investigated in biopsies of atopic dermatitis (AD) patients and compared with in vitro 
data. Skin biopsy specimens from an acute lesion and from surrounding normal appearing (non-
lesional) skin of AD patients as well as specimens from healthy volunteers were collected after 
informed consent. As expected, morphologies of the non-lesional and healthy skins (figure 5a 
and 5b) appear identical. HA staining in the normal epidermis is finely localised around the 
cells of the basal and spinous layers (figure 5d and e). AD lesional skin sections, on the other 
hand, display distinctive epidermal hyperplasia and parakeratosis (figure 5c) (Oyoshi et al., 
2009). Yet, HA staining is as intense as in normal skin sections and is localised in all 
intercellular spaces of lesional epidermis (figure 5f).  
The dermis was partially visible on the sections. As often demonstrated previously (Wells et 
al., 1991), it is filled with compact HA staining (figure 5d and 5e) except in AD lesions where 
dermal HA staining is strikingly reduced (figure 5f).  
The mRNA expression level of HAS was measured using quantitative PCR in similar 2-mm 
deep punch biopsies of 11 healthy skins, 9 non lesional skins, and 9 lesional skins of AD 
patients. The mean expression of HAS1 mRNA in the whole skin (mostly epidermis) is 
decreased by 50% in both non-lesional and lesional skin of AD patients compared with healthy 
skin (figure 5g). On the other hand, the relative expression level of HAS3 mRNA is similar in 
healthy and non-lesional skin but increases approximately 10-fold in AD lesions. The relative 
expression level of HAS2 mRNA does not differ significantly between samples. In view of their 
stable expression in skin models (see supplementary figure 2), hyaluronidases were not 
evaluated in the biopsies. 
 
Upregulation of HB-EGF can drive differential HAS expression in AD skin 
 
Several studies have shown that growth factors influence HAS expression in keratinocytes 
(Sayo et al., 2002; Karvinen et al., 2003; Pasonen-Seppanen et al., 2003) and we have just 
shown that the HAS1/HAS3 ratio increases 100-fold in response to anti-EGFR treatment (see 
supplementary figure 3c). Immunohistochemical HB-EGF labelling of the biopsy specimens in 
the current study shows very little signal in healthy skin but a strong marking in both lesional 
and non-lesional AD epidermis (figure 6). This is in line with the results obtained in our 
previous study (Mathay et al., 2011). To determine if HB-EGF can induce differential HAS 
expression in the epidermis, we measured the mRNA levels of HAS1, HAS2 and HAS3 in RHE 
treated for 10 days with recombinant human HB-EGF at concentrations ranging from 0 to 25 
ng.mL-1. HAS2 mRNA is scarcely expressed even after HB-EGF exposure (data not shown) 
but HAS3 mRNA expression is dose-dependently elevated upon incubation with HB-EGF 
(figure 6g). Conversely, HAS1 expression decreases at high concentrations of the EGFR ligand 
(figure 6g).  
Our data thus confirm that epidermal HB-EGF is induced in AD patients and that it can 
modulate the expression of HAS1 and HAS3 in the RHE model with the same pattern as in AD 
itself.  
    
DISCUSSION 
This study was undertaken to assess the regulation of HA production by HASs during 
spontaneous differentiation of human epidermal keratinocytes in two models (monolayer 
cultures and RHE) and in AD skin. The models contain no dermis, making epidermal analysis 
easier but preventing potential paracrine effects from the dermis. For instance, EGF signalling 
is able to influence HA metabolism in fibroblasts (Rock et al., 2012) and KGF may regulate 
HA metabolism of keratinocytes (Karvinen et al., 2003). 
In both culture models, HA was found to accumulate with keratinocyte differentiation in 
parallel with an increase in HAS1 mRNA expression and a decrease in HAS3. The expression 
of HAS2 mRNA was very low both in vitro and in vivo, and decreased further during 
differentiation of the monolayer, suggesting that HAS2 plays a minor role in keratinocyte 
physiology. Similarly, we could not show any role for hyaluronidases as HYAL1 and HYAL2 
expressions were stable in monolayers and decreased during epidermal reconstruction. 
Furthermore, both the monolayers and RHE contained mostly high molecular weight (>106 Da) 
HA even in non-differentiating conditions when HAS1 was weakly expressed. Human 
epidermal HA is also composed of high molecular weight (>106 Da) HA species (Tammi et al., 
1991). 
At first sight, our results may seem discordant with existing knowledge as published data 
indicate that HAS3 is responsible for HA synthesis in keratinocytes while HAS1 produces HA 
in fibroblasts (Sayo et al., 2002; Yamada et al., 2004). However, we believe that the results 
obtained in the current study based on spontaneous differentiation of human keratinocytes 
induced by cell density are very relevant for skin physiology. In fact, the role of HAS3 in 
epidermal HA production was previously demonstrated by incubating keratinocytes with 
cytokines like TGFβ or IFN-γ (Sayo et al., 2002), growth factors like EGF or KGF (Pienimaki 
et al., 2001; Karvinen et al., 2003; Pasonen-Seppanen et al., 2003), or RA (Saavalainen et al., 
2005; Pasonen-Seppanen et al., 2008). All these factors can interfere with the balance of HASs. 
In our study we also tested RA and EGFR blockade on keratinocyte monolayers. Anti-EGFR 
antibodies increased the HAS1/HAS3 expression ratio 100-fold and RA decreased that ratio 
100-fold. RA also increased HAS2 expression, thus completely reversing the changes in HAS1, 
HAS2 and HAS3 expression observed under spontaneous differentiation. Interestingly, RA was 
also found to increase HB-EGF expression (Giltaire et al., 2009), suggesting that HB-EGF 
could explain the increase in HAS3 expression as observed in other models (Monslow et al., 
2009). In addition, treatment of RHE with HB-EGF decreased the HAS1/HAS3 ratio 50-fold. 
All these observations allow us to postulate that HAS1 and HAS3 are distinctly regulated in 
keratinocytes, possibly by the EGFR pathway, and likely function under different 
circumstances: HAS1 is the most important HA synthesizing enzyme during epidermal 
differentiation while the role of HAS3 emerges during pathological conditions.  
An important result of the current study is the fact that HA, though produced at high levels 
during differentiation, is not necessary for this process. Indeed, the expression profile of 
differentiation markers was not modified when HA was depleted using either 4MU or 
hyaluronidase treatment. Moreover, the HA is deposited mainly in keratinocyte layers in RHE 
which are IVL negative and KRT10 low at later time points. This might also indicate an 
independent regulation of keratinocyte differentiation and HA synthesis.  
 Correspondingly, the double-knockout mice that lack HAS1 and HAS3 do not present a 
disruption of epidermal differentiation (Mack et al., 2011) although HAS2 could exert a 
compensatory effect in that case. Our results thus clarify the discrepancy in the literature about 
the link between HA and keratinocyte differentiation. Some publications report that HA induces 
differentiation (Bourguignon et al., 2006; Farwick et al., 2011) whereas others demonstrate that 
HA inhibits differentiation (Maytin et al., 2004; Passi et al., 2004). Our study suggests HA is 
not involved in the process of spontaneous epidermal differentiation. 
However, HA could become critical in pathological conditions. In particular, AD lesional skin 
showed a striking upregulation of HAS3 and downregulation of HAS1 with no significant 
changes in the amount or pattern of HA in the epidermis. We can only speculate on the 
consequences of an inverted HAS1/HAS3 ratio in AD lesions. There is no hint that this switch 
could induce changes in the HA molecular size profile, at least based on the measurements of 
HA molecular weights during spontaneous keratinocyte differentiation. However, recent 
experiments have shown that HAS3, but not HAS1, can induce HA receptor-independent 
pericellular coats and shedding of microvesicles  (Rilla et al., 2013b; Siiskonen et al., 2014). 
HAS3 can also function with a lower concentration of intracellular UDP-linked substrates than 
HAS1 (Rilla et al., 2013a). Any of these elements could be involved in the switch to 
inflammation-activated keratinocytes. 
Our study also highlights the role of EGF ligands in keratinocyte pathophysiology. In particular, 
HB-EGF was overexpressed in AD skin and the HAS expression pattern in RHE incubated with 
HB-EGF was identical to the pattern observed in AD lesion, suggesting that HB-EGF could be 
a critical factor able to modulate HAS expression in AD skin. However, the strong labelling of 
HB-EGF in non-lesional epidermis of AD patients indicates that HB-EGF likely needs synergy 
with other molecules such as inflammatory cytokines to regulate HAS expression pattern in AD 
lesions. 
In conclusion, our study indicates that the balance of HA produced by distinct HAS enzymes is 
critical for regulating keratinocyte physiology. We have shown that HAS1 is involved in the 
production of HA by keratinocytes during normal differentiation although suppression of HA 
does not prevent this process. In contrast, HAS3 is likely expressed by keratinocytes in response 
to stressing or in pathological conditions such as AD while HAS1 is downregulated. HB-EGF 
may play a role in HAS3 induction. Future studies are required to elucidate the detailed 
mechanisms governing the balance between HAS1 and HAS3 epidermal expression during 
differentiation and in pathological conditions. 
 
MATERIALS AND METHODS 
 
Skin biopsies 
 
See supplementary material online 
 
Cell culture and reconstruction of the epidermis 
 
See supplementary material online 
 
Measurements of hyaluronan concentrations 
 
The cell medium was collected to measure extracellular HA; then cells were treated with trypsin 
to collect pericellular HA; finally they were lysed with 0.1 M Tris-HCl buffer (pH 7.4) 
containing 10 mM CaCl2 to measure intracellular or intra-tissular HA. The medium and extracts 
were incubated overnight with 500 mU/ml Pronase (Sigma-Aldrich, Bornem, Belgium) at 
55°C. HA concentration was quantified using Hyaluronan DuoSet kit (R&D systems, 
Abingdon, UK). Total cell protein concentration was measured using Pierce Protein Assay 
(ThermoScientific, Illinois, USA).  
 
Total RNA isolation and quantitative PCR  
Total RNA was extracted from monolayers using High Pure RNA isolation kit (Roche, Basel, 
Switzerland) and from RHE using RNeasy kit (Qiagen, Hilden, Germany). cDNA was 
generated from 1 μg of total RNA using the Super Script II reverse transcriptase kit (Invitrogen, 
Merelbeke, Belgium). cDNA was amplified using FastStart Universal SYBR Green Master 
(Roche, Basel, Switzerland) in a 7300 real-time PCR machine (Applied Biosystems, Lennik, 
Belgium). Primers (Sigma-Aldrich, Bornem, Belgium) were used at 300 nM. They are listed in 
Table S1. mRNA levels were normalized to geometric mean of RPL13A and TBP mRNA 
expression levels (Minner and Poumay, 2009). Data were analyzed using the ∆∆CT quantitative 
method (Livak and Schmittgen, 2001). 
 
Labelling  
RHE or biopsies were fixed in 4% formalin in 70% ethanol–5% glacial acetic acid to improve 
HA detection (Lin et al., 1997), embedded in paraffin, and sectioned with a microtome. Tissue 
sections were deparaffinised, rehydrated and rinsed in water. Sections were blocked and 
permeabilized for 1 h in PBS containing 0.2% bovine serum albumin (PAA Laboratories 
GmbH, Pasching, Austria) and 0.02% Triton X-100 (Merck, Darmstadt, Germany). For HA 
labelling, slides were incubated overnight at 4°C with biotinylated hyaluronan-binding complex 
(generously given by Professor Markku Tammi) diluted 1:50 in the above solution. After 
washing, all slices were incubated for 1 h in fluorescein streptavidin (Vector laboratories, CA, 
USA). Nuclei were counterstained with Hoechst 33258 (Molecular Probes Inc., OR, USA). 
Slices were mounted using Mowiol (Sigma-Aldrich, Steinheim, Germany) for observation on 
an Olympus AX70 microscope. Immunolabeling of HB-EGF (Mathay et al., 2008), IVL, and 
KRT10 (Frankart et al., 2012) was performed as described. 
 
Statistical analysis  
HA concentration and mRNA expression data were analyzed using one-way ANOVA and 
Holm-Sidak test on results of three independent experiments in each model. Statistical analyses 
of biopsy mRNA expression levels were performed using either paired Wilcoxon signed-rank 
test or Mann–Whitney test (Bonferroni corrected). 
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FIGURE LEGENDS 
 
Figure 1  
HA concentration and HAS expression correlate with epidermal differentiation in 
keratinocyte monolayers.  
HA amounts (means±SEM of triplicates) in culture medium (a), released by trypsin incubation 
(pericellular HA; b), or measured in total cell extracts (intracellular HA; c) of keratinocyte 
autocrine monolayers were determined every 48h, starting two days before confluence (C-2d) 
until four days after confluence (C+4d) and normalized to cell proteins. The expression of the 
3 main HA synthases (HASs) was measured by real-time PCR during the growth of autocrine 
monolayers (d) or in  confluent cultures incubated for 18h with all-trans retinoic acid (10-9-10-
6mol.L-1) or DMSO as control (f). Epidermal differentiation was analyzed by measuring the 
relative expression levels of KRT10 and IVL mRNA (e and g). The mRNA levels at C-2d (e) 
and DMSO (g) were arbitrarily fixed at 1. The y-axis is a logarithmic scale and error bars 
represent 95% confidence intervals (n=3, ANOVA 1RM, *P<0.05, **P<0.01, ***P<0.001 vs 
C-2d or DMSO). 
 
Figure 2 
Analysis of HA depletion by 4-methylumbelliferone (4MU) or Streptomyces 
hyaluronidase (Hase) on relative mRNA expression levels of involucrin (IVL), filaggrin 
(FLG) and keratin 10 (KRT10) in monolayer culture of keratinocytes during their 
epidermal differentiation. Keratinocytes were grown in monolayer and the differentiation was 
induced by confluence. Cells were treated with 1U/ml of Hase (a, c and e) or 0.5mM of 4MU 
(b, d and f) during 48h at each confluence stages. The expression of KRT10 (a and b), IVL (c 
and d) and FLG (e and f) was measured by real-time PCR and expression levels were 
normalized to the average expression of two housekeeping genes (RPLP0 and TBP). The 
mRNA levels in control conditions were taken as references and arbitrarily fixed at 1.  The y 
axis is a logarithmic scale and error bars represent 95% confidence intervals (n=3, ANOVA 
2RM analysis of variance) 
 
Figure 3 
HA concentration and distribution during the reconstruction of human epidermis.  
Reconstructed human epidermises (RHEs) were obtained after 1, 3, 5, 7, 9 and 11 days of 
growth. The newly synthesized HA in the medium (a) and in the RHE layer (b) were measured 
every 48 h and normalized with respect to total cellular protein concentration. Data are shown 
as means ± SEM (n=3, ANOVA 1RM, *P<0.05, **P<0.01, ***P<0.001 vs day 1). (c) RHEs 
obtained after 1, 3, 5, 7, 9 and 11 days of growth on polycarbonate filter at the air-liquid 
interface were fixed, processed for histology and stained for morphology (hematoxylin/eosin) 
or for HA (green) and nuclei (Hoechst 33258; blue). The differentiation process was assessed 
based on the staining of KRT10 and IVL. Bar = 50 μm. 
 
Figure 4  
mRNA expression of HA synthases during the reconstruction of human epidermis.  Total 
RNA from reconstructed human epidermis (RHE) obtained after 1, 3, 5, 7, 9 and 11 days of 
growth was extracted, reverse transcription was performed, and cDNA was analyzed by real-
time PCR. The expression levels of HAS1-3, keratin10 (KRT10) and Loricrin (Lor) were 
normalized to the average expression of two housekeeping genes (RPLP0 and TBP). The 
mRNA level at day 1 was taken as reference and arbitrarily set at 1. The y-axis is a logarithmic 
scale and error bars represent 95% confidence intervals (n=3, ANOVA 1RM, 
*P<0.05, **P<0.01, ***P<0.001 vs day 1). 
 
Figure 5  
HA distribution and mRNA expression of HA synthases in atopic dermatitis (AD) skin 
samples. Sections of normal skin (a,d), non-lesional skin of AD patient (b,e), and lesional skin 
of AD patient (c,f) were stained with hematoxylin/eosin/Saffron (a,b,c) or labelled with a 
biotinylated HA binding protein (d,e,f). Bar = 100 μm. (g) Total RNA was extracted from 
biopsies of 11 normal skins, 9 non-lesional skins of AD patients, and 9 lesional skins of AD 
patients. Real-time PCR was performed and the values are expressed relative to the means of 
10 healthy samples. Statistical analyses were performed by a paired Wilcoxon signed-rank test 
for the comparison of lesional versus non-lesional AD skin and by a Mann–Whitney test for the 
comparisons of lesional and non-lesional versus healthy skin (*P<0.05,  ***P<0.001). 
  
 
Figure 6 
HB-EBF distribution in AD skin and mRNA expression of HA synthases during 
reconstruction of human epidermis incubated with HB-EGF. Sections of normal skin (a,d), 
non-lesional skin of AD patient (b,e), and lesional skin of AD patient (c,f) were labelled (a,b,c)  
or not (d,e,f)  with an antibody against HB-EBF (d,e,f). Bar = 50 μm. (g) Reconstructed human 
epidermises (RHEs) were incubated at first day of reconstruction with concentrations of rHB-
EGF ranging from 0 to 25 ng.mL-1. rHB-EGF was renewed every two days until 11th day of 
reconstruction. Total RNA was extracted from each culture and real-time PCR was performed. 
The mRNA levels of 0 ng.mL-1 rHB-EGF were arbitrarily set at 1 and error bars represent 95% 
confidence intervals (n=3, ANOVA 1RM, *P<0.05 vs 0 ng.mL-1 condition).  
 
  
SUPPLEMENTARY DATA 
 
Supplementary figure 1 
Size distribution of HA present in the medium of monolayer cultures and recombinant 
human epidermis (RHE)  
Human keratinocytes were grown as either (a) autocrine monolayers with differentiation 
induced by cell confluence; they were analysed 2 days before confluence (C-2d), at confluence 
(C) and 2 and 4 days after confluence (C+2d and C+4d); or (b) reconstructed epidermis (RHE); 
they were analyzed after 5, 7, 9 and 11 days of growth. The newly synthesized HA released 
into the medium every 48 h was chromatographed on a column of Sephacryl S-1000 together 
with HA standard fragments of 2500, 500 and 150 kDa. HA was measured in each fraction and 
shown as mean ± SD (n=3). The peak maximum of HA standard fragments is represented in 
each graph (). Graph (c) compares the size distributions of post-confluent monolayer (C+4d) 
and RHE (11d). 
  
Supplementary figure 2 
mRNA expression of hyaluronidases (HYAL1 and HYAL2) during differentiation of 
keratinocyte cultures or reconstruction of human epidermis (RHE).  
Keratinocytes were grown in two models as described in Supplementary figure 1. Total RNA 
was extracted from each culture condition from two days before confluence (C-2d) until four 
days after confluence (C+4d) in monolayers (a,b) or after 1, 3, 5, 7, 9 or 11 days of tissue 
reconstruction (c,d). Reverse transcription was performed and cDNA was analyzed by real-time 
PCR. Expression levels of HYAL1 and HYAL2 were normalized to the average expression of 
two housekeeping genes (RPLP0 and TBP). The mRNA level at C-2d was taken as reference 
and arbitrarily fixed at 1. The error bars represent 95% confidence intervals (n=3, ANOVA 
1RM, *P<0.05, ***P<0.001 vs C-2d or 1d). 
 
  
  
Supplementary figure 3 
Abundance of total and phosphorylated EGF receptor (EGFR and pEGFR) and amount 
of HAS1 and HAS3 during epidermal differentiation and treatment with an EGFR 
neutralizing antibody  
(a) Keratinocytes were grown as autocrine monolayers and differentiation was induced by cell 
confluence. Proteins were extracted from each culture condition, from two days before 
confluence (C-2d) until four days after confluence (C+4d). Western blot analysis was 
performed using antibodies against EGFR and pEGFR. Keratin 10 was used to assess 
differentiation and RPL13a, as loading control. (b,c) Subconfluent cultures (C-2d) were 
incubated or not (CTL) with 10 µg/ml of EGFR neutralizing antibody (LA1) during 48 h. 
Proteins (b) were extracted from each culture condition and analysed as in (a); total RNA (c) 
was extracted from each condition, reverse transcribed, and the cDNA was analysed and 
quantified by real-time PCR. Expression levels of HAS1 and HAS3 were normalized to the 
average expression of two housekeeping genes (RPLP0 and TBP). The mRNA levels in control 
conditions were taken as references and arbitrarily fixed at 1. The y-axis in (c) is a logarithmic 
scale and error bars represent 95% confidence intervals (n=3, one-way analysis of variance, 
***P<0.001 vs CTL conditions). 
 Supplementary figure 4 
Analysis of HA depletion by 4-methylumbelliferone (4MU) or Streptomyces hyaluronidase 
(Hase) in monolayer culture of keratinocytes during their epidermal differentiation  
Keratinocyte monolayers were exposed to various concentrations of 4MU or to 1 U/ml of Hase 
at different confluence stages from two days before confluence (C-2d) until four days after 
confluence (C+4d). (a) Cellular viability was analysed and expressed as percentage of surviving 
cells compared to untreated control. (b,c) Cells were treated with 0.5 mM of 4MU (b) or 1 U/ml 
of Hase (c) during 48 h at each confluence stage. The amount of newly synthesized HA released 
in the medium during that time was measured and normalized to total cell protein content. Data 
are shown as means ± SD (n=3, two-way analysis of variance, *P<0.05, **P<0.01, 
***P<0.001).  
  
SUPPLEMENTARY MATERIALS AND METHODS 
 
 
Chemicals 
 
Retinoic acid (RA), 4-methylumbelliferone (4MU) and Streptomyces hyaluronidase (Hase) 
were purchased from Sigma Aldrich (Bornem, Belgium). Neutralizing antibody against EGFR 
(clone LA1) was obtained from Millipore (Brussels, Belgium). EGF was obtained from R&D 
Systems (Abingdon, UK). Rabbit antihuman EGF receptor (EGFR), rabbit antihuman 
phosphor-EGFR Tyr 1173, and rabbit antihuman RPL13 antibodies were purchased from Cell 
Signaling (Leiden, The Netherlands). Mouse antihuman keratin 10 was from Dako (Heverlee, 
Belgium). HA standards for measurement of HA molecular weight were obtained from Hyalose 
(Oklahoma City, OK, USA). 
 
Skin biopsies 
 
Following approval by the ethics committees of the University Hospital in Liège and Clinique 
St-Luc in Namur, both in Belgium, this study was conducted in accordance with the Declaration 
of Helsinki. Nine volunteers suffering from atopic dermatitis (AD) underwent a superficial 
2mm skin punch biopsy on lesional and surrounding non-lesional skin as described (Mathay et 
al., 2011). Abdominal samples obtained from plastic surgery were used as healthy controls and 
for in vitro culture experiments. All the subjects gave written informed consent before the 
examinations. 
 
Cell culture and reconstruction of the epidermis 
 
Keratinocyte cultures were grown in autocrine culture conditions as described earlier (Minner 
et al., 2010) and in polycarbonate culture inserts for reconstructed human epidermis (RHE) 
models described earlier (Frankart et al., 2012; Minner et al., 2010). Recombinant human HB-
EGF (259-HE) was from R&D Systems (Abingdon, UK). 
 
Measurement of HA molecular weight  
The culture medium was collected, subjected to gel filtration on a column of Sephacryl S-1000 
(Amersham Biosciences, Uppsala, Sweden) and eluted at 70 µl/min with 0.15 M sodium 
acetate, 0.1% CHAPS (Sigma-Aldrich, Steinheim, Germany). After chromatography, HA was 
measured in each fraction as described previously. Samples of known molecular weight HA 
were chromatographed on the same columns.  
 
MTT assay procedure 
 
A volume of 0.5 ml of MTT solution (Sigma-Aldrich, Bornem, Belgium) at 0.5 mg/ml in 
defined culture medium was added onto cultures and incubated for 1 h at 37 °C (5% CO2). After 
incubation, the MTT solution was discarded and 1 ml of isopropanol (Merck, Overijse, 
Belgium) was added to each culture. The extraction process of blue MTT solution was 
performed during 10 min at room temperature on a shaking platform. The Optical Density (OD) 
of the blue MTT solution at 540 nm was determined and the mean OD540 of the untreated 
controls was set to represent 100% of viability. The results are expressed as percentage of these 
controls.  
 
Protein extraction and Western blotting 
 
Keratinocytes were lyzed and scraped into Laemmli sample buffer (62.5 mM Tris-HCl, 2% 
sodium dodecyl sulphate, 8.7% glycerol, 0.05% bromophenol blue, 0.2% dithiothreitol). 
Extracted proteins were analyzed using SDS-polyacrylamide gel electrophoresis and 
transferred onto polyvinylidene difluoride (PVDF) membranes (GE Healthcare, Diegem, 
Belgium). Membranes were incubated for 1 h with specific antibodies diluted in PBS buffer 
containing 1% Tween 20 and 5% nonfat powdered milk. After a washing step, the membranes 
were incubated with HRP-conjugated antirabbit antibody (Cell Signaling, Leiden, The 
Netherlands). The chemiluminescence substrate from Roche (Basel, Switzerland) was used to 
visualize the recognized protein bands. For visualization, an ImageQuant LAS 4000mini (GE 
Healthcare, Diegem, Belgium) was used. 
 
 
  
Table S1: real-time PCR primers 
 
Gene Symbol Forward primer (5' - 3') Reverse primer (5' - 3') 
   
FLG GGGCACTGAAAGGCAAAAAG CACCATAATCATAATCTGCACTACCA 
HAS1 CCTCACCAACCGCATGCT GGACGAGGGCGTCTCTGA 
HAS2 CTGGGACGAAGTGTGGATTATG GATGAGGCTGGGTCAAGCAT 
HAS3 GCCCTCGGCGATTCG TGGATCCAGCACAGTGTCAGA 
HYAL1 CCTCACCAACCGCATGCT TCCTTGATGGCCTGACATGA 
HYAL2 GCACTCCCAGTCTACGTCTTCA GCACTCTCGCCAATGGTAGAG 
IVL TGAAACAGCCAACTCCAC TTCCTCTTGCTTTGATGGG 
KRT10 AATCAGATTCTCAACCTAACAAC CTCATCCAGCACCCTACG 
LOR TCATGATGCTACCCGAGGTTTG CAGAACTAGATGCAGCCGGAGA 
RPL13a CTCAAGGTCGTGCGTCTGAA TGGCTGTCACTGCCTGGTACT 
TBP TCAAACCCAGAATTGTTCTCCTTAT CCTGAATCCCTTTAGAATAGGGTAGA 
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